Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on June 30, 2025
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire
·
June 30, 2025
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been …
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
GlobeNewswire
·
June 30, 2025
Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Senti Bio Participates in Nasdaq Amplify Spotlight Series
GlobeNewswire
·
June 30, 2025
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using …
Joint Commission Launches a Transformative Approach to Healthcare Accreditation
GlobeNewswire
·
June 30, 2025
OAKBROOK TERRACE, Illinois, June 30, 2025 (GLOBE NEWSWIRE) -- Joint Commission today launched Accreditation 360: The New Standard, a transformational approach to hospital and healthcare accreditation and certification. Leveraging data analytics with a …
GCANRx Announces Uplisting to New Market Tier
GlobeNewswire
·
June 30, 2025
BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products is pleased to announce …
INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
GlobeNewswire
·
June 30, 2025
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce the addition of Platelet-Rich Plasma …
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis
GlobeNewswire
·
June 30, 2025
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two positive early cardiogenic shock Phase 2 …
EVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm Sign Strategic Supply Agreement
GlobeNewswire
·
June 30, 2025
SHANGHAI and CAIRO, June 30, 2025 (GLOBE NEWSWIRE) -- EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and Zhejiang Jinhua CONBA, one of China’s most prominent …
EVA制药与浙江金华康恩贝生物制药签署战略供应协议
GlobeNewswire
·
June 30, 2025
上海，开罗, June 30, 2025 (GLOBE NEWSWIRE) -- EVA制药公司，作为推动中东和非洲地区医疗创新与可及性的领先制药企业之一，与浙江金华康恩贝生物制药集团，中国最著名的制药集团之一，签署了战略供应协议，标志着全球医疗合作迈出了重要一步。 该协议在2025年中国国际医药原料药展（CPHI China 2025）期间签署，代表了各自地区内两个有影响力企业之间的高层合作。该协议旨在支持更可持续、更灵活和更安全的药品供应链，最终为新兴市场的患者提供更大的可及性。 …
Clover Health Set to Join Russell 3000® Index
GlobeNewswire
·
June 30, 2025
WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part …
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
GlobeNewswire
·
June 30, 2025
Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U. …
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
GlobeNewswire
·
June 30, 2025
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting …
Microbot Medical® Added to the Russell Microcap® Index
GlobeNewswire
·
June 30, 2025
HINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition …
Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting
GlobeNewswire
·
June 30, 2025
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more patient-friendly alternative to intravitreal injections, with the potential to …
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
GlobeNewswire
·
June 30, 2025
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern …
Medical Supplierz Expands Online Access to Surgical and Diagnostic Equipment
EIN Presswire
·
June 30, 2025
KUWAIT, KUWAIT, June 30, 2025 /EINPresswire.com/ -- Medical Supplierz has expanded its digital marketplace to streamline the purchase of diagnostic and surgical equipment for healthcare providers globally. This initiative addresses the growing need for …
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
GlobeNewswire
·
June 30, 2025
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
GlobeNewswire
·
June 30, 2025
RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by …
Synergy CHC Corp. (NASDAQ: SNYR) Secures Landmark Retail and Distribution Wins Across North America for FOCUSfactor Supplements and Functional Beverages
GlobeNewswire
·
June 30, 2025
WESTBROOK, Maine, June 30, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, today announced a major wave of North American retail and distribution gains across both …
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
GlobeNewswire
·
June 30, 2025
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently …